The Vertex Pharmaceuticals-backed genomic analytics platform developer has now raised approximately $88m in funding altogether.

Genomics plc, a UK-based precision healthcare technology developer backed by drug manufacturer Vertex Pharmaceuticals, closed a $30m funding round on Monday. F-Prime Capital, an investment affiliate of financial services and investment group Fidelity, provided the funding together with university venture fund Oxford Sciences Innovation (OSI), Foresite Capital and Lansdowne Partners. Founded in 2014, Genomics has…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.